SGLT2 inhibitors may reduce resting BP and skeletal muscle reflexes independent of glycemic control Medha Baranwal31 Aug 2022 12:00 PM ISTDallas, TX: Recent data have shown a novel role for SGLT2 inhibitors independent of glycemic control, in reducing resting blood pressure (BP) and...
Dapagliflozin safe and effective in type 2 diabetes regardless of background CV medications: JAMA Medha Baranwal29 July 2022 11:00 AM ISTUSA: Data from a prespecified secondary analysis of DECLARE-TIMI 58 show the clinical safety and benefit of dapagliflozin in a broad range of patients...
Dapagliflozin promising treatment for male fertility in diabetic patients: Study Medha Baranwal23 July 2022 10:00 AM ISTChina: Findings from a recent study published in the Asian Journal of Andrology suggest that dapagliflozin may be a promising treatment for male...
Glenmark Pharma launches Sitagliptin and its FDCs for Type 2 diabetes in India Ruchika Sharma7 July 2022 3:28 PM ISTThe medicines will be available under the brand name SITAZIT, SITAZIT- M, SITAZIT- M ER and SITAZIT D.
Glenmark gets CDSCO Panel nod to study antidiabetic FDC containing Dapagliflozin, Sitagliptin, Metformin Susmita Roy27 Jun 2022 6:15 PM ISTNew Delhi: Granting the waiver of bioequivalence study, the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO)...
All SGLT-2 inhibitors found promising for diabetes management in Indian settings: JAPI Medha Baranwal11 Jun 2022 11:30 AM ISTMaharashtra: SGLT2 Inhibitors could be considered as an add-on to all antidiabetic agents currently used for diabetes management in the Indian...
Dapagliflozin action on HFrEF not impacted by frailty: Data from DAPA-HF trial Medha Baranwal6 May 2022 10:00 AM ISTUK: Findings from a post hoc analysis of the DAPA-HF trial suggests that the protective effects of dapagliflozin in patients having heart failure with...
Dapagliflozin safe in hospitalized patients with COVID-19 with preserved or reduced kidney function Dr. Kamal Kant Kohli2 May 2022 9:45 AM ISTWashington, DC: In a recent randomized clinical trial of hospitalized patients with COVID-19 and cardio-metabolic risk factors, the sodium-glucose...
Dapagliflozin associated with improved outcomes in heart failure patients regardless of frailty Dr. Kamal Kant Kohli26 April 2022 9:45 AM ISTA post-hoc analysis of the DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure) randomized control trial found that...
NPPA fixes retail prices of 15 formulations, ceiling price of Framycetin Ruchika Sharma19 April 2022 4:06 PM ISTNew Delhi: National Pharmaceutical Pricing Authority (NPPA), Ministry of Chemicals and Fertilizers, Government of India has fixed retail prices of 15...
Add on Dapagliflozin exhibits inconsequential antidiabetic effect in kids with type 2 diabetes Medha Baranwal16 April 2022 11:15 AM ISTUSA: In an Intention-to-treat analysis of children, adolescents, and young adults with type 2 diabetes who received dapagliflozin with the standard of...
Dapagliflozin effective in treating type 1 diabetes Dr. Nandita Mohan26 Feb 2022 5:42 PM ISTType 1 diabetes is a worrying condition as ones immune system destroys insulin-making cells in the pancreas. Recent data published in PLOS One...
